|
| |
Thrombotargets Corporation and Dr. Cam Patterson, Director of the Carolina
Cardiovascular Biology Center at the University of North Carolina to create a
Joint Venture for the exploitation of their proprietary technologies.
Representatives sign Memorandum of Intent. Durham, July, 3rd, 2007.
Thrombotargets Corporation and Dr. Cam Patterson have signed a Memorandum of
Intent for the establishment of a Thrombosis and Hemostasis specialised CRO that
will provide new drug discovery services based on both university and
Thrombotargets proprietary technologies.
Under the terms of this Memorandum, Dr. Patterson will act as an advisor in the
installation of key technologies and laboratory service and the technical
operation of the laboratory, while Thrombotargets will be responsible for
installation of its proprietary technologies, laboratory design and build out,
management of the corporation and laboratory, and the lab’s new drug discovery
services sales and marketing activities.
It is anticipated that this new laboratory will be fully operational by the
first quarter of 2008.
“This Memorandum executed between Thrombotargets and Dr. Patterson, not only
represents an agreement to create an important business venture in the US, it
will lead to a very important business and scientific relationship with the
Carolina Cardiovascular Biology Center”.explained Steven A. Hite, Thrombotargets’
COO.
“Today we have taken the first step towards the global commercialization of CCBC
techniques and models,” stated Dr. Patterson, MD, FACC, and Director of the CCBC
“The combination of our unique, proprietary technologies in forming this CRO
represents the first of its kind in the industry with the capability to
streamline and greatly improve the new drug discovery process.
About Thrombotargets
Thrombotargets (
www.thrombotargets.com ) is a privately held group of biotech companies
focused on the discovery and development of innovative drugs in Haemostasis,
Thrombosis and Atherosclerosis. The company has a number of potential new drugs
in development internally, and its proprietary targets and innovative uHTS
platforms are used in internal drug discovery programs, and are also available
for client drug discovery projects.
About CCBC
The Carolina Cardiovascular Biology Center, established in 2000, is a
multidisciplinary, multidepartmental facility that serves as a focal point for
interactions among basic, translational, and clinical scientists studying all
aspects of cardiovascular disease. Areas of specific interest include
atherosclerosis and other vascular diseases, angiogenesis and cardiovascular
development, cardiovascular physiology, and diseases of hemostasis.
Contact:
Steven A Hite
COO
stevehite@thrombotargets.com
| |
|
